5 books every budding entrepreneur needs to read

Startup School

Before you even start thinking about starting your own company, read these books. Photo by Utamaru Kido/Getty Images

You thought you were done with homework, but, if you're an entrepreneur looking to start a company, that's not the case. The startup world is a lot of fun, but also a lot of work and preparation.

So, what kind of homework should you do? Unfortunately, watching Shark Tank and HBO's Silicon Valley can only take you so far. You need to know about pre-money valuations, convertible notes, liquidation preferences, control provisions, and so much more. Fortunately, there are plenty of books to get you up to speed. Yes, books — do you remember those? Turns out plain old books can be very useful if you're looking to get involved with the even the highest tech parts of the startup world. So here are five books to get you started.

The Launch Pad: Inside Y Combinator, Silicon Valley's Most Exclusive School for Startups

Photo via Amazon.com

As a startup founder, you'll need to know what Y Combinator is, how it works, what the people are like, and how great founders and mentors conduct themselves. This book offers a behind the scenes look at the most elite startup incubator/accelerator. Why is it the most elite? Because it keeps producing unicorns (companies valued at over $1 billion) — think AirBnb, Dropbox, Twitch, Stripe. With this book, you'll really get a sense of the day to day conversations and challenges that startups face. It is also just a really entertaining book and a great starting point.

Venture Deals: Be Smarter Than Your Lawyer and Venture Capitalist

Photo via Amazon.com

After reading Launch Pad, it is time to get down to business. Venture Deals is a fairly in-depth breakdown of the relationship between investors and startup founders. It runs through typical VC titles, processes, and incentives. Perhaps most importantly, it goes into the economic and control provisions of the term sheet. You'll want a pen and paper to take plenty of notes when going through this one. Do not expect this book to always be fun, but do expect to learn a lot. If you can make it through this one and really absorb what is being said then you might actually be serious about the startup world, so good job.

Measure What Matters: How Google, Bono, and the Gates Foundation Rock the World with OKRs

Photo via Amazon.com

Whether you'll be a founder, investor, reporter, or just want to be a successful person, you need to set lofty goals, write them down, share them, and stick to them. OKR stands for objectives and key result. This book is less about startups and more about pushing yourself to achieve more. OKRs force you to break down your goals in metrics that can be tracked. For example, I knew I wanted to meet with hundreds of startups per year for my investment job. But how many exactly? How do I set a goal for that? Simple — just say you need to meet with at least two startups per day for a least one hour. That means at least 10 startups per week (five working days), or over 40 per month. Set lofty goals, so that you fail to achieve 30 percent of them.

Startup CEO: A Field Guide to Scaling Up Your Business

Photo via Amazon.com

Time to step inside the shoes of the CEO — must be nice to be in charge, right? I'm sure it is nice in some ways, but it is also an unbelievable amount of work. This book goes through every last detail — in detail. You may feel overwhelmed at times, but you might also feel ready to manage a company. There is much more to managing a company than can be found in a single book, but this is a great breakdown of the day-to-day activities. It has tips on how to be organized, prioritize time, grow your key employees, and interact with the board of directors. Sure, you'll still need to build a great product that customers want, and you'll still need to have great interpersonal and communication skills, but at least this book describes the details of how to operate.

​Zero to One: Notes on Startups, or How to Build the Future​

Photo via Amazon.com

The final book in this short list will drive you to think big — and think differently. Think about building a dominating monopoly. Yes, monopolies are a good thing when you're the one making the business. I hope that concept is not too upsetting, but you should be ruthless when you are out there competing. That means giving your customers something amazing that your competition can't even compete with. If you think about it, the big tech companies pretty much dominate at least one market. Google has search and maps. Facebook, since owning Instagram, has social media. Amazon has logistics. If you're going to start a startup you should aim to be 10 times better than any competition in one key way. You want to clearly differentiate your product from your competition. Zero to One teaches you how to think that way, and so much more.

So, there you have it. I think these five books will give you a good starting point. There are a dozen or more other books you should also read about innovating, investing, and managing, but you must start somewhere. This list gives you a little bit of everything to get you started.

Now, you just have to actually start.

------

Mark Friday is an associate leading venture capital investments at Houston-based Cathexis Holdings LP.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings